Krishnan, Chairman and CEO of Krystal Biotech. "With multiple near-term readouts ... The Company cautions investors that amounts presented in accordance with its definition of non-GAAP combined R&D ...

Debut Biotech, a company innovating new molecules through advanced biotechnology, is partnering with Image Skincare to launch ...

Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and profits thanks to an important cancer drug. It's developing other products ...

Industry leaders say uncertainty in funding, clinical development and manufacturing is driving companies to embrace digital ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

Safety results showed no increase in immune-mediated adverse events (34.0% vs 38.4%) or treatment-related adverse events ...

Despite the emphasis on detachment from ideas, X employees do have significant skin in the game when projects spin out.

Alt5 Sigma suspended Peter Tassiopoulos just two months after the company announced a $1.5 billion deal involving the ...

Tardigrades make a unique damage suppressor protein that researchers are working to harness for medicine, space, agriculture, ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

Still, the recently released 2025-30 Arizona Bioscience Roadmap, as well as several academic, community and local government ...